Reuse of a transplanted liver graft: First experience in South America
Domingo Balderramo, María Eugenia Romero, Álvaro Alcaraz, Martín Barrabino, Martín Maraschio – 20 October 2014
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus–coinfected liver transplant recipients
Isabel Campos‐Varela, Stephanie Straley, Eliana Z. Agudelo, Laurie Carlson, Norah A. Terrault – 20 October 2014
Serotonin in liver tumor: Friend or foe?
Qing Pang, Chang Liu, Jing‐Yao Zhang, Kai Qu, Si‐Dong Song, Su‐Shun Liu, Xin‐Sen Xu – 20 October 2014
Reply
Andrea Lisotti, Francesco Azzaroli, Giuseppe Mazzella – 20 October 2014
Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory‐Sobol, William T. Symonds, John G. McHutchison, Fernando E. Membreno – 16 October 2014 – Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment‐experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates.
Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory‐Sobol, William T. Symonds, John G. McHutchison, Fernando E. Membreno – 16 October 2014 – Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment‐experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates.
Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus
Eric M. Yoshida, Mark S. Sulkowski, Edward J. Gane, Robert W. Herring, Vlad Ratziu, Xiao Ding, Jing Wang, Shu‐Min Chuang, Julie Ma, John McNally, Luisa M. Stamm, Diana M. Brainard, William T. Symonds, John G. McHutchison, Kimberly L. Beavers, Ira M. Jacobson, K.
Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus
Eric M. Yoshida, Mark S. Sulkowski, Edward J. Gane, Robert W. Herring, Vlad Ratziu, Xiao Ding, Jing Wang, Shu‐Min Chuang, Julie Ma, John McNally, Luisa M. Stamm, Diana M. Brainard, William T. Symonds, John G. McHutchison, Kimberly L. Beavers, Ira M. Jacobson, K.
Creating an environment that supports innovation
Michael Abecassis – 14 October 2014
Performance of modified‐release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts
Aisling Considine, J. Michael Tredger, Michael Heneghan, Kosh Agarwal, Marianne Samyn, Nigel D. Heaton, John G. O'Grady, Varuna R. Aluvihare – 13 October 2014 – Clinical outcomes, dose changes, and dose‐equalized tacrolimus concentrations were examined sequentially in 129 liver transplantation (LT) recipients after successful conversion to once daily modified‐release tacrolimus either early (within 1 month) or late (>1 month) after LT. The data were compared with data for a group of 60 patients maintained on twice daily conventional‐release tacrolimus.